Novo Nordisk Raises 2026 Outlook as Wegovy Pill Sales Surge

Novo Nordisk Upgrades Annual Guidance After Strong Third-Quarter Performance

Danish pharmaceutical company Novo Nordisk raised its 2026 financial outlook for the third time this year on Wednesday, November 4, after stronger-than-expected sales of its Wegovy weight-loss pill helped drive quarterly revenue and operating profit above market forecasts.

The company now expects adjusted sales and operating profit growth of between a 2% decline and a 2% increase at constant exchange rates.

This represents an improvement from its previous forecast of flat growth to a 6% decline.

The guidance upgrade reflects stronger demand for GLP-1 medicines, particularly obesity treatments, across the United States and international markets.

Novo Nordisk reported third-quarter adjusted sales of approximately 79.20 billion Danish kroner (DKK), exceeding analysts' expectations of around DKK 73.22 billion.

Adjusted operating profit reached DKK 31.72 billion, representing growth of 27% at constant exchange rates and exceeding the market forecast of approximately DKK 28.39 billion.

The company's oral Wegovy treatment emerged as a major growth driver.

Sales of the Wegovy pill reached DKK 5.39 billion during the quarter, increasing 53% from the previous quarter and surpassing analyst expectations.

The results provided a boost to Novo Nordisk as it seeks to strengthen its competitive position against US pharmaceutical rival Eli Lilly.

Novo Nordisk Q3 2026 Financial Highlights

Growth rates at constant exchange rates exclude currency translation effects. Adjusted and reported operating profit differ because of exceptional items.

The results indicate that the company's underlying commercial performance improved even as certain exceptional charges affected reported profitability.

Wegovy Pill Sales Rise 53% to DKK 5.39 Billion

The Wegovy pill was the standout product in Novo Nordisk's third-quarter performance.

The oral weight-loss treatment generated DKK 5.39 billion in revenue, equivalent to approximately $810 million.

Sales increased 53% compared with the second quarter.

The result exceeded the market consensus of DKK 4.62 billion by approximately DKK 770 million.

The stronger-than-expected performance demonstrates growing commercial demand for oral obesity treatment.

Wegovy's tablet formulation provides an alternative to injectable weight-management medicines.

For some patients, an oral treatment may be preferable to injections, although suitability depends on medical assessment, prescribing requirements and treatment characteristics.

The company launched the pill in the United States in January 2026.

Its rapid commercial expansion has become an important component of Novo Nordisk's strategy to regain momentum in the obesity drug market.

Wegovy Pill Sales Exceed Analyst Expectations

Wegovy pill Q3 2026 sales versus consensus

DKK billion

 

Actual third-quarter Wegovy pill sales exceeded the analyst consensus by approximately 16.7%.

The difference between actual sales and expectations was a significant factor behind the positive investor response.

US Market Accounts for Majority of Wegovy Pill Revenue

The United States remained the largest market for the Wegovy pill.

US sales reached approximately DKK 4.18 billion during the third quarter.

International markets contributed around DKK 1.22 billion.

The US therefore accounted for more than three-quarters of the product's quarterly revenue.

This concentration highlights the importance of American demand to Novo Nordisk's near-term growth.

However, it also creates exposure to US pricing, insurance reimbursement and competitive conditions.

International expansion could gradually diversify revenue.

The company has begun introducing the treatment across additional markets, although commercial performance will depend on regulatory approvals, reimbursement arrangements and patient access.

Wegovy Pill Geographic Sales Breakdown

Geographic figures are rounded, so components may not sum exactly to the reported total.

The US remains the principal contributor, but international launches are becoming increasingly important.

US Prescriptions Cross 8 Million Since Launch

Novo Nordisk reported approximately 3.6 million Wegovy pill prescriptions in the United States during the third quarter.

Cumulative prescriptions since the product's January launch exceeded 8 million.

The figures indicate substantial early adoption.

However, prescription counts should not be interpreted as the number of individual patients receiving treatment.

Patients may receive multiple prescriptions over time.

The commercial value of prescriptions also depends on dosage, pricing, discounts and reimbursement arrangements.

Nevertheless, the prescription data provide evidence of significant demand for the oral formulation.

The company estimates that the Wegovy pill accounts for approximately 80% of new-to-brand prescriptions within the relevant US oral obesity treatment market across reimbursed, cash-pay and telehealth channels.

The estimate reflects Novo Nordisk's assessment of the market and may change as competitors expand.

Prescription Growth Shows Signs of Seasonal Moderation

Despite the strong quarterly sales performance, Novo Nordisk acknowledged that prescription growth had flattened in recent weeks.

Chief Executive Officer Mike Doustdar attributed the moderation partly to seasonal factors.

The company expects demand could strengthen around Christmas and the beginning of the new year.

However, this remains an expectation rather than a confirmed recovery.

Seasonal patterns can influence demand for weight-management treatments.

Patient interest, healthcare appointments and insurance arrangements may affect prescription activity.

Investors will therefore monitor whether the recent moderation is temporary or indicates a broader slowdown.

Sustained prescription growth will be important to supporting the company's ambitious expectations for oral obesity medicines.

Novo Nordisk Raises 2026 Outlook for Third Time

The latest guidance revision marks Novo Nordisk's third increase in its 2026 financial outlook.

The company now expects adjusted sales growth at constant exchange rates of between −2% and +2%.

It expects adjusted operating profit growth within the same range.

Previously, management anticipated adjusted sales and operating profit performance ranging from a 6% decline to no growth.

The revised forecast reflects improved expectations for GLP-1 medicine sales.

However, the guidance still allows for a modest decline in annual adjusted revenue and profit.

This distinction is important.

The company is forecasting better performance than previously expected, but it has not guaranteed positive annual growth.

Novo Nordisk 2026 Guidance Comparison

The guidance revision indicates improved operating momentum while acknowledging continuing challenges in the US market.

Adjusted Operating Profit Rises 27%

Novo Nordisk reported adjusted operating profit of DKK 31.72 billion in Q3 2026.

The figure represented 27% growth at constant exchange rates.

It exceeded analysts' expectations of approximately DKK 28.39 billion.

However, reported operating profit declined 9% at constant exchange rates to DKK 23.01 billion.

The difference reflected exceptional charges.

Novo Nordisk recognised approximately DKK 8.7 billion in non-cash impairment charges during the quarter.

These included DKK 4.6 billion associated with ziltivekimab and DKK 4.1 billion related to adjustments in its manufacturing network.

The company also benefited from a favourable comparison with the previous-year quarter, when it recognised substantial transformation costs.

Investors therefore need to distinguish between adjusted operating performance and reported profitability.

Nine-Month Financial Performance Reflects Mixed Trends

For the first nine months of 2026, Novo Nordisk reported revenue of approximately DKK 254.51 billion.

Reported revenue increased 11% in Danish kroner and 13% at constant exchange rates.

Adjusted sales for the period reached approximately DKK 227.75 billion.

The difference reflects the company's adjustments for certain exceptional items.

Reported operating profit for the nine-month period reached DKK 109.69 billion.

Adjusted operating profit was approximately DKK 97.97 billion.

The results demonstrate the importance of understanding the company's adjusted reporting framework when comparing quarterly and year-to-date performance.

Novo Nordisk Nine-Month 2026 Financial Results

The nine-month figures provide context for the company's revised full-year outlook.

Novo Nordisk Shares Rise Following Earnings Announcement

Novo Nordisk shares advanced following the release of the results.

The stock gained as much as 6.6% during early trading in Copenhagen.

By approximately 10:23 GMT, shares were trading around 1.9% higher.

The positive reaction reflected stronger-than-expected earnings and the improved financial outlook.

However, the company's shares remain substantially below their previous peak.

Novo Nordisk's market valuation had exceeded $600 billion during the height of investor enthusiasm for obesity treatments.

Its shares subsequently declined by more than 70% from their peak amid competitive pressure, weaker growth and changes in management.

The latest results suggest improving commercial momentum.

Nevertheless, a single strong quarter does not establish that the company's longer-term recovery is complete.

Competition With Eli Lilly Remains Intense

Novo Nordisk continues facing significant competition from US pharmaceutical company Eli Lilly.

Both companies are major participants in the market for GLP-1-based obesity and diabetes treatments.

Eli Lilly's injectable Zepbound has gained substantial market share.

Novo Nordisk's injectable Wegovy has faced increasing competitive pressure.

The companies are also competing in oral weight-management medicines.

Novo Nordisk has established an early commercial position with the Wegovy pill.

However, Eli Lilly's Foundayo oral treatment is gaining market attention.

The competition is likely to influence pricing, product development and patient access.

For investors, the central question is whether Novo Nordisk can sustain its leadership in oral obesity treatment as additional products enter the market.

Oral Weight-Loss Medicines Become Strategic Growth Opportunity

Novo Nordisk is placing greater emphasis on oral obesity medicines as part of its long-term strategy.

CEO Mike Doustdar has indicated that oral treatments could account for as much as half of the obesity medicine market by 2030.

This represents a company expectation rather than an established market forecast.

Oral treatments may appeal to patients who prefer tablets over injections.

They may also create opportunities to expand treatment access through different healthcare channels.

However, commercial adoption depends on clinical effectiveness, tolerability, pricing and prescribing requirements.

Manufacturing capacity and reimbursement arrangements will also influence market growth.

Novo Nordisk's early success with the Wegovy pill has strengthened its position in this emerging segment.

Injectable Wegovy Sales Decline in the United States

Despite the success of the oral formulation, Novo Nordisk continues facing pressure in its injectable Wegovy business.

US sales of injectable Wegovy declined 13% at constant exchange rates during the third quarter.

The decrease reflects competitive conditions in the injectable obesity treatment market.

However, combined US sales across the Wegovy franchise increased 21%.

This demonstrates that growth in the pill formulation more than offset weakness in the injectable product within the overall US franchise.

The result highlights the importance of product diversification.

Novo Nordisk is increasingly relying on oral treatment growth to support its obesity portfolio.

Nevertheless, injectable medicines remain an important part of the market.

The company will need to manage both product categories as competition intensifies.

Wegovy Franchise Maintains Strong Position in New Patient Starts

Novo Nordisk estimates that the Wegovy franchise accounts for more than 50% of new patient starts among branded obesity medicines in the United States.

This includes the company's broader treatment portfolio.

The figure suggests that Wegovy remains a major participant despite competition from Eli Lilly.

However, new patient starts are not the same as total market share by revenue.

Market share can be measured using prescriptions, patients, units or sales value.

These measures may produce different results.

Investors will therefore monitor both prescription trends and financial performance.

The company's ability to retain patients and sustain treatment demand will influence long-term revenue.

Wegovy Pill Expands Into Eight Markets

Novo Nordisk has continued expanding the international availability of its oral weight-loss treatment.

By the end of the third quarter, the Wegovy pill had been launched in the United States, United Arab Emirates, United Kingdom and Germany.

Subsequent launches in four additional countries increased the total number of markets to eight.

The international rollout provides opportunities to diversify revenue beyond the United States.

However, pharmaceutical launches depend on country-specific regulatory and commercial conditions.

Pricing and reimbursement arrangements can vary substantially.

Some markets may have restrictions on coverage or prescribing.

The pace of international expansion will therefore depend on both regulatory access and commercial execution.

Ozempic Pill Adds to Oral GLP-1 Portfolio

Novo Nordisk is also expanding its oral diabetes treatment portfolio.

The company launched the Ozempic pill in the United States in May 2026.

Management reported encouraging early prescription momentum.

Weekly new-to-brand prescriptions were approximately 100% higher than levels recorded before the launch under the Rybelsus brand.

The development reflects Novo Nordisk's broader strategy of offering GLP-1 treatments across multiple formulations.

However, the commercial performance of diabetes treatments must be assessed separately from obesity medicines.

Regulatory indications, reimbursement arrangements and patient populations differ.

The expansion of oral GLP-1 products may provide additional growth opportunities.

CagriSema Pipeline Remains Important to Future Growth

Novo Nordisk continues investing in its pharmaceutical development pipeline.

One important programme is CagriSema, a combination treatment being studied for obesity and diabetes.

The company reported that CagriSema achieved 21% weight loss at week 68 in the REDEFINE 9 trial.

In the REIMAGINE 5 trial involving adults with type 2 diabetes and obesity, CagriSema achieved 12.4% weight loss compared with 9.1% for the specified tirzepatide comparator dose.

The company is preparing for a potential US launch of CagriSema in early 2027, subject to regulatory approval.

Clinical trial outcomes should not be interpreted as guarantees of regulatory approval or commercial success.

The programme nevertheless represents an important component of Novo Nordisk's efforts to expand its treatment portfolio.

New Oral Drug Development Continues

Novo Nordisk has also initiated the phase 3 AMAZE 9 trial involving oral zenagamtide.

The study began in September 2026.

The development reflects continued investment in next-generation obesity medicines.

The pharmaceutical industry is exploring treatments with different mechanisms, dosing schedules and administration methods.

These innovations may expand the range of available treatment options.

However, drug development involves clinical, regulatory and commercial risks.

Successful early research does not guarantee that a medicine will reach the market.

Novo Nordisk's ability to maintain a competitive pipeline will be important as existing products face greater competition.

US Pricing Changes Create Challenges for 2027

Novo Nordisk plans to reduce US list prices for Wegovy and Ozempic from January 1, 2027.

The company intends to set the monthly list price at $675.

This represents reductions of approximately 50% for Wegovy and 35% for Ozempic.

The changes are intended to address pricing and access considerations in the US market.

However, list prices do not necessarily represent the amounts paid by insurers, healthcare providers or patients.

Actual realised prices depend on rebates, discounts and commercial arrangements.

Novo Nordisk has indicated that the changes will affect cash flow in 2027.

The financial impact will depend on whether increased treatment volumes can offset lower realised prices.

Lower Prices Could Support Access but Pressure Revenue

Pricing changes create a trade-off for pharmaceutical companies.

Lower prices may improve affordability and expand access to treatment.

This could support prescription volumes.

However, lower revenue per prescription may reduce margins unless offset by higher demand or operational efficiencies.

The outcome depends on patient uptake, insurance coverage and competitive conditions.

For Novo Nordisk, the pricing changes will be particularly important because the United States remains a major contributor to revenue.

Investors will monitor how the company balances market share growth with profitability.

The financial effects may become clearer during 2027.

Patent and Exclusivity Risks Remain Important

Novo Nordisk faces additional challenges from the loss of semaglutide exclusivity in certain international markets.

Patent and regulatory exclusivity protections influence the period during which pharmaceutical companies can market products without specified forms of generic competition.

When protections expire, additional manufacturers may enter eligible markets.

This can create pricing pressure.

However, the timing and commercial impact vary by country.

Regulatory approvals, manufacturing requirements and patent disputes may affect market entry.

Novo Nordisk has identified international exclusivity changes as a potential challenge for 2027.

The company will need to offset these pressures through new products, increased volumes and operational efficiency.

China Remains a Challenging Market

Novo Nordisk also expects continued pressure in China.

The country represents an important pharmaceutical market, but competition and pricing conditions can affect commercial performance.

Healthcare procurement policies and reimbursement arrangements may influence product economics.

The company has not provided detailed 2027 guidance at this stage.

However, management has identified China as one of the markets requiring attention.

International expansion will therefore involve both opportunities and challenges.

Novo Nordisk's ability to manage pricing and competition across different regions will influence its future earnings performance.

Chief Financial Officer Transition Announced

Novo Nordisk also announced a leadership change.

Chief Financial Officer Karsten Munk Knudsen will leave the company at the end of December 2026.

He has served as CFO since 2018.

The company has appointed Luigi La Corte, currently finance chief at Galderma, as his successor.

The transition comes during an important period for Novo Nordisk.

The company is adjusting its commercial strategy, expanding oral treatments and managing pricing pressures.

Financial leadership will play an important role in capital allocation, cost management and investor communication.

However, the company has not indicated that the CFO transition changes its revised 2026 financial guidance.

Key Growth Drivers and Risks for Novo Nordisk

These factors will determine whether the company's recent earnings improvement develops into sustained growth.

Implications for the Global Pharmaceutical Industry

Novo Nordisk's results demonstrate the continuing commercial importance of obesity treatments.

The market has become a major source of growth for pharmaceutical companies.

Demand is being supported by expanding treatment options and increased awareness of obesity-related health conditions.

However, commercial success depends on more than patient demand.

Companies must address affordability, insurance coverage, manufacturing capacity and regulatory requirements.

Competition is also encouraging investment in new formulations and treatment combinations.

The success of the Wegovy pill suggests that oral treatments could become an increasingly important part of the market.

Nevertheless, injectable medicines remain significant, and future market shares are uncertain.

Implications for Pharmaceutical Investors

For investors, Novo Nordisk's guidance upgrade represents an improvement in the company's near-term outlook.

The strong performance of the Wegovy pill indicates that the company has developed a meaningful growth opportunity.

However, the revised annual forecast remains relatively cautious.

Adjusted sales and operating profit could still decline by up to 2% at constant exchange rates.

This reflects ongoing challenges in pricing, competition and geographic performance.

Investors will therefore need to assess both the positive prescription trends and the risks affecting future profitability.

The company's 2027 outlook will be particularly important because of planned US price reductions and international exclusivity changes.

Key Indicators Investors Will Monitor

These indicators will help determine whether Novo Nordisk can sustain the improvement demonstrated in the third quarter.

Outlook for Novo Nordisk in 2027

Novo Nordisk enters the final months of 2026 with stronger commercial momentum.

The Wegovy pill has exceeded expectations and become an important growth driver.

International launches could expand the product's addressable market.

The company is also advancing new treatments that may support future revenue.

However, several challenges remain.

US pricing changes will affect the economics of key products.

Competition from Eli Lilly is intensifying across injectable and oral treatments.

Patent and exclusivity changes may create additional pressure in certain international markets.

Management has not yet provided formal 2027 guidance and expects to address the outlook in February.

Investors will therefore monitor fourth-quarter sales, prescription trends and early indications of the financial impact from pricing changes.

The longer-term outlook will depend on Novo Nordisk's ability to sustain demand while maintaining competitive pricing and profitability.

Conclusion

Novo Nordisk raised its 2026 financial outlook for the third time on November 4, 2026, after stronger-than-expected third-quarter earnings and rapid growth in sales of its Wegovy weight-loss pill.

The Danish pharmaceutical company now expects adjusted sales and operating profit growth of between −2% and +2% at constant exchange rates, improving from its previous forecast of −6% to 0%.

Third-quarter adjusted revenue reached approximately DKK 79.20 billion, while adjusted operating profit increased 27% to DKK 31.72 billion at constant exchange rates.

The Wegovy pill generated DKK 5.39 billion in sales, rising 53% sequentially and exceeding analyst expectations.

The product's performance has strengthened Novo Nordisk's position in oral obesity treatment as competition with Eli Lilly intensifies.

However, weakness in injectable Wegovy sales, planned US price reductions and international exclusivity changes remain important challenges.

The company's shares rose following the announcement, reflecting improved investor confidence.

The sustainability of the recovery will depend on continued prescription growth, successful international expansion and the company's ability to manage pricing pressure.

For the pharmaceutical industry, Novo Nordisk's results reinforce the growing commercial importance of oral obesity treatments and the competitive transformation of the global GLP-1 medicine market.